| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 09/19/2001 | CN1313769A Pharmaceutical combination comprising A COX-2 inhibitor and a iNOS inhibitor |
| 09/19/2001 | CN1313756A Oral liquid mucoadhesive compositions |
| 09/19/2001 | CN1313755A Oral mucoadhesive compositions containing gastrointestinal actives |
| 09/19/2001 | CN1313754A Oral liquid mucoadhesive compositions |
| 09/19/2001 | CN1313750A Toothpaste comprising fine and coarse calcium carbonate |
| 09/19/2001 | CN1313385A Process for preparing genetically engineered efficient medicine target-introduced to human liver cells |
| 09/19/2001 | CN1313343A N-terminal modified protein compositions and methods therefor |
| 09/19/2001 | CN1313284A N-(3-benzofuryl) urea derivative |
| 09/19/2001 | CN1313280A Benzheterocyclic derivatives |
| 09/19/2001 | CN1313112A Aloe capsule prepared from natural aloe and its preparing process |
| 09/19/2001 | CN1313111A Health-care medical wine for invigorating function of kidney and strengthening bone |
| 09/19/2001 | CN1313105A 'Chinese-medicinal pad' and its preparing process |
| 09/19/2001 | CN1313096A Health-care tonic buccal lozenge |
| 09/19/2001 | CN1313094A Tonic oral liquid for building up body |
| 09/19/2001 | CN1071332C Enterokinetic benzamide |
| 09/19/2001 | CN1071331C Anti-helicobacter acyl derivatives of azolones |
| 09/19/2001 | CN1071330C Anti-helicobacter urea and thiourea derivatives of azolones |
| 09/19/2001 | CN1071329C Aryl glycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds |
| 09/19/2001 | CN1071328C Arginine angalogues having nitric oxide synthase inhibitor activity |
| 09/19/2001 | CN1071123C Preparatory Chinese-medicine for treatment of hepatitis and hepatoascites |
| 09/19/2001 | CN1071115C Compound medicine for gastroenteritis and gastroenteritic ulcer |
| 09/18/2001 | US6291522 Cyclopentane heptan(ENE)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents |
| 09/18/2001 | US6291516 Contacting the cell with a composition including at least one cyclic amp agonist. |
| 09/18/2001 | US6291491 Treatment of type ii diabetes and obesity; antidepressants; decrease gut motility. |
| 09/18/2001 | US6291485 Treatment of post-ptca restenosis |
| 09/18/2001 | US6291481 Conditions related to a hampered or impaired gastric emptying and more generally to treat conditions related to a hampered or impaired gastrointestinal transit. |
| 09/18/2001 | US6291473 Treating anxiety, depression, post-traumatic stress disorder, inflammatory diseases, obesity, in mammals |
| 09/18/2001 | US6291465 Biphenyl derivatives |
| 09/18/2001 | US6291459 Calcilytic compounds |
| 09/18/2001 | US6291458 Morpholinobenzamide salts |
| 09/18/2001 | US6291457 Compounds having cytokine inhibitory activity |
| 09/18/2001 | US6291454 Dithiepino[6,5-b]pyridines, and related compositions and methods |
| 09/18/2001 | US6291452 Cholecystokinin antagonists. |
| 09/18/2001 | US6291450 Carboxylic acid substituted heterocycles, derivatives thereof and methods of use |
| 09/18/2001 | US6291435 Reduce the virulence of an epec organism, which method comprises contacting an epec organism with a composition comprising a monosaccharide or an oligosaccharide sequence |
| 09/18/2001 | US6291425 Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| 09/18/2001 | US6291195 Generating ligands which bind preferential human receptors; incubate cells expressing preferential binding protein with modulator, detect adjustment in binding activity |
| 09/18/2001 | US6290985 By chewing the gum, the medicament or agent is released from the product. |
| 09/18/2001 | US6290953 May be a conjugate which includes a targeting portion adapted to target the conjugate to a specific cell type or anatomical location. |
| 09/18/2001 | US6290946 Administering to the animal a therapeutically effective amount of a polymer having a plurality of pendant acid functional groups which are directly attached to the polymer backbone or attached to the polymer backbone by a spacer group. |
| 09/18/2001 | US6290934 Agent for the promotion of oral hygiene and oral health |
| 09/18/2001 | US6290933 Silica hydrogel particles, the particles containing about 10 to about 35% by weight water having a morphology being characterized by glass conchoidal fracture surfaces |
| 09/18/2001 | CA2238879C Thereapeutic applications for the anti-t-bam (cd40-l) monoclonal antibody 5c8 |
| 09/18/2001 | CA1341293C Alpha-subunit of the mac-1 leukocyte adhesion receptor |
| 09/15/2001 | WO2001066747A2 Proteins named fctrx and nucleic acids encoding same |
| 09/15/2001 | CA2401552A1 Proteins named fctrx and nucleic acids encoding same |
| 09/13/2001 | WO2001066754A1 Human antibodies against eotaxin and their use |
| 09/13/2001 | WO2001066746A2 G-protein coupled receptor related polypeptides |
| 09/13/2001 | WO2001066742A2 G-protein coupled receptors |
| 09/13/2001 | WO2001066716A1 Polypeptide having phosphodiesterase activity |
| 09/13/2001 | WO2001066706A1 Protein tyrosine phosphatase polynucleotides, polypeptides, and antibodies |
| 09/13/2001 | WO2001066597A2 Inflammation-related gene |
| 09/13/2001 | WO2001066594A2 Human protein kinases and protein kinase-like enzymes |
| 09/13/2001 | WO2001066548A1 New aza-indolyl derivatives |
| 09/13/2001 | WO2001066544A2 Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers |
| 09/13/2001 | WO2001066543A2 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives |
| 09/13/2001 | WO2001066533A1 1,5-benzothiazepines and their use as hypolipidaemics |
| 09/13/2001 | WO2001066525A1 New ccr5 modulators: benzimidazoles or benzotriazoles |
| 09/13/2001 | WO2001066164A1 Modified protein matrices |
| 09/13/2001 | WO2001066125A1 DNA ENCODING HUMAN ACID-SENSING ION CHANNEL BNaC4 (ASIC4) |
| 09/13/2001 | WO2001066123A2 Composition consisting of phy906 and chemotherapeutic agents |
| 09/13/2001 | WO2001066119A2 Pharmaceutical compositions including alginates |
| 09/13/2001 | WO2001066112A1 Urease inhibitors |
| 09/13/2001 | WO2001066107A2 Treatment of diseases associated with cytokine production with inhibitors of the tec family of protein tyrosine kinases |
| 09/13/2001 | WO2001066100A2 Pharmaceutical composition |
| 09/13/2001 | WO2001066089A2 Pharmaceutical compositions comprising cannabis |
| 09/13/2001 | WO2001066081A2 Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients |
| 09/13/2001 | WO2001065949A1 Treatment of infection in animals |
| 09/13/2001 | WO2001028498A3 Retro-anandamides, high affinity and stability cannabinoid receptor ligands |
| 09/13/2001 | WO2001028497A3 Novel bicyclic cannabinoid agonists for the cannabinoid receptor |
| 09/13/2001 | WO2001016288A3 Dna encoding the human serine protease c-e |
| 09/13/2001 | WO2001013906A3 Compositions including modafinil for treatment of eating disorders and for appetite stimulation |
| 09/13/2001 | WO2001009138A3 Chemokine receptor antagonists and methods of use therefor |
| 09/13/2001 | WO2000063370A3 Nucleic acids coding for novel truncated cart proteins, corresponding truncated cart polypeptides and their use for therapeutic and diagnostic purposes |
| 09/13/2001 | WO2000059886A3 Benzimidazole abd imidazolophyridine derivaties, their preparation and their use as selective modulators of bradykinin b2 (=bk-2) receptors |
| 09/13/2001 | US20010021758 Drugs, medical diagnosis |
| 09/13/2001 | US20010021516 An isolated nucleic acid molecule comprising a polynucleotide having nucleotide sequence atleast 95% identical to a sequence selected from a nucleotide sequence encoding a TRID polypeptide having specific amino acid sequence |
| 09/13/2001 | US20010021393 Antibodies from eggs immunized with urease of Helicobacter |
| 09/13/2001 | CA2402466A1 Composition consisting of phy906 and chemotherapeutic agents |
| 09/13/2001 | CA2402179A1 Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers |
| 09/13/2001 | CA2402039A1 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives |
| 09/13/2001 | CA2401549A1 G-protein coupled receptor related polypeptides |
| 09/13/2001 | CA2401541A1 Human protein kinases and protein kinase-like enzymes |
| 09/13/2001 | CA2401524A1 New ccr5 modulators: benzimidazoles or benzotriazoles |
| 09/13/2001 | CA2401454A1 G-protein coupled receptors |
| 09/13/2001 | CA2401398A1 Dna encoding human acid-sensing ion channel bnac4 (asic4) |
| 09/13/2001 | CA2401323A1 Treatment of diseases associated with cytokine production with inhibitors of the tec family of protein tyrosine kinases |
| 09/13/2001 | CA2401055A1 1,5-benzothiazepines and their use as hypolipidaemics |
| 09/13/2001 | CA2400527A1 Urease inhibitors |
| 09/13/2001 | CA2399921A1 Protein tyrosine phosphatase polynucleotides, polypeptides, and antibodies |
| 09/13/2001 | CA2399111A1 New aza-indolyl derivatives |
| 09/12/2001 | EP1132403A1 Tgf g beta1 inhibitor peptides |
| 09/12/2001 | EP1132389A1 New aza-indolyl derivatives for the treatment of obesity |
| 09/12/2001 | EP1132092A1 Coupling factor 6 inhibitor and potentiator and use thereof |
| 09/12/2001 | EP1132089A1 Extract from loquat seeds against fibrosis |
| 09/12/2001 | EP1131467A2 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
| 09/12/2001 | EP1131445A1 Human phospholipases |
| 09/12/2001 | EP1131431A2 Nucleic acids and polypeptides having altered expression in the t84 gut barrier model |
| 09/12/2001 | EP1131428A2 Immunoglobulin superfamily proteins |
| 09/12/2001 | EP1131425A2 Inflammation-associated genes |